Brokers Offer Predictions for RAPP Q1 Earnings

Rapport Therapeutics, Inc. (NASDAQ:RAPP) – Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for Rapport Therapeutics in a research note issued to investors on Wednesday, August 12th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($1.63) per share for the quarter. HC Wainwright has a “Buy” rating and a $66.00 price objective on the stock. The consensus estimate for Rapport Therapeutics’ current full-year earnings is ($4.09) per share. HC Wainwright also issued estimates for Rapport Therapeutics’ Q2 2027 earnings at ($1.68) EPS, Q3 2027 earnings at ($1.73) EPS and Q4 2027 earnings at ($1.77) EPS.

RAPP has been the subject of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Friday, July 17th. Wall Street Zen cut Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Citigroup reiterated a “market outperform” rating on shares of Rapport Therapeutics in a report on Tuesday, June 2nd. Truist Financial started coverage on shares of Rapport Therapeutics in a research note on Monday, May 18th. They set a “buy” rating and a $56.00 price target on the stock. Finally, BTIG Research restated a “buy” rating and issued a $65.00 price objective on shares of Rapport Therapeutics in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Rapport Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $61.57.

Rapport Therapeutics Stock Down 0.8%

Shares of Rapport Therapeutics stock opened at $47.36 on Friday. The firm has a market cap of $2.27 billion, a PE ratio of -15.58 and a beta of 0.97. Rapport Therapeutics has a 52 week low of $13.86 and a 52 week high of $49.50. The business’s fifty day simple moving average is $40.66 and its 200-day simple moving average is $35.20.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07).

Institutional Investors Weigh In On Rapport Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. KBC Group NV acquired a new position in Rapport Therapeutics in the first quarter valued at $30,000. Meeder Asset Management Inc. purchased a new position in shares of Rapport Therapeutics during the fourth quarter worth about $37,000. Russell Investments Group Ltd. acquired a new stake in shares of Rapport Therapeutics during the third quarter worth about $43,000. State of Wyoming acquired a new stake in shares of Rapport Therapeutics during the second quarter worth about $65,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Rapport Therapeutics by 64.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock valued at $70,000 after purchasing an additional 905 shares during the last quarter.

Insider Buying and Selling

In other news, CEO Abraham Ceesay sold 28,958 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the completion of the sale, the chief executive officer owned 486,108 shares in the company, valued at approximately $23,338,045.08. The trade was a 5.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $40.05, for a total transaction of $743,808.60. Following the completion of the transaction, the insider owned 6,280,525 shares of the company’s stock, valued at approximately $251,535,026.25. The trade was a 0.29% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 72,281 shares of company stock valued at $3,269,892 over the last ninety days. 12.48% of the stock is currently owned by corporate insiders.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.